| GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug |
Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period. |
zacks.com |
2025-05-15 12:55:14 |
Czytaj oryginał (ang.) |
| GSK splashes out $1.2bn up-front for liver treatment still in clinical trials |
GSK PLC (LSE:GSK, NYSE:GSK) has struck a deal to acquire a drug to treat and prevent the progression of steatotic liver disease, poised for phase III clinical trials, for up to $2 billion. The disease affects up to 5% of the global population, the FTSE 100 group says, and is an "area of significant unmet medical need with limited treatment options". |
proactiveinvestors.co.uk |
2025-05-14 06:55:30 |
Czytaj oryginał (ang.) |
| GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion |
The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone payments of $800 million. |
wsj.com |
2025-05-14 06:42:00 |
Czytaj oryginał (ang.) |
| GSK to buy efimosfermin for up to $2 billion |
British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine from Boston Pharmaceuticals, for up to $2 billion. |
reuters.com |
2025-05-14 06:24:16 |
Czytaj oryginał (ang.) |
| GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals' lead asset, efimosfermin alfa. Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic. |
businesswire.com |
2025-05-14 06:14:00 |
Czytaj oryginał (ang.) |
| ITeos, GSK discontinue lung cancer therapy development |
iTeos Therapeutics and partner GSK said on Tuesday that they terminated the development of their experimental lung cancer therapy after its failure to significantly improve progression free survival in a mid-stage trial. |
reuters.com |
2025-05-13 12:21:19 |
Czytaj oryginał (ang.) |
| India's GlaxoSmithKline Pharma reports profit rise on strong demand |
India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs. |
reuters.com |
2025-05-13 11:45:18 |
Czytaj oryginał (ang.) |
| Glaxo (GSK) Upgraded to Buy: Here's What You Should Know |
Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-12 17:05:49 |
Czytaj oryginał (ang.) |
| Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices |
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices. |
youtube.com |
2025-05-12 16:36:24 |
Czytaj oryginał (ang.) |
| GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis |
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis. |
businesswire.com |
2025-05-09 13:00:00 |
Czytaj oryginał (ang.) |
| GSK price target lowered to 1,355 GBp from 1,450 GBp at Morgan Stanley |
Morgan Stanley lowered the firm's price target on GSK to 1,355 GBp from 1,450 GBp and keeps an Underweight rating on the shares. |
https://thefly.com |
2025-05-07 17:23:38 |
Czytaj oryginał (ang.) |
| 5 Reasons GSK Looks Good |
GSK's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Both turnover and EPS growth exceeded expectations, and the company's guidance indicates that the stock's forward P/E is competitive too. Additionally, GSK's medium-to-long-term financial prospects look good too, based on the company's latest outlook, which also works in the stock's favour. |
seekingalpha.com |
2025-05-05 15:37:58 |
Czytaj oryginał (ang.) |
| Here's Why GSK (GSK) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-01 14:46:07 |
Czytaj oryginał (ang.) |
| GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance |
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs. |
zacks.com |
2025-04-30 16:46:04 |
Czytaj oryginał (ang.) |
| GSK plc (GSK) Q1 2025 Earnings Conference Call Transcript |
GSK plc (NYSE:GSK ) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ET Company Participants Constantin Fest - Head of IR Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Julie Brown - CFO David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JP Morgan Kerry Holford - Berenberg Jo Walton - UBS Graham Parry - Bank of America Simon Baker - Redburn Rajan Sharma - Goldman Sachs Sarita Kapila - Morgan Stanley Constantin Fest Ladies and gentlemen, a very warm welcome to this GSK Q1 2025 Results Call. My name is Constantin Fest, new head of IR at GSK, and I'm delighted to be joined today by Emma Walmsley, Luke Miels and Julie Brown. |
seekingalpha.com |
2025-04-30 16:32:06 |
Czytaj oryginał (ang.) |
| Here's Why GSK (GSK) is a Strong Momentum Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-04-30 14:55:56 |
Czytaj oryginał (ang.) |
| Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | GSK Leads Cervarix Market Amid Global Vaccination Efforts |
The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc leads the market, with Cervarix targeting HPV-linked conditions like cervical cancer. Advanced HPV vaccines and personalized immunization strategies are emerging trends. The report details market dynamics, historical data, and future growth projections. The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc leads the market, with Cervarix targeting HPV-linked conditions like cervical cancer. Advanced HPV vaccines and personalized immunization strategies are emerging trends. The report details market dynamics, historical data, and future growth projections. |
globenewswire.com |
2025-04-30 13:41:00 |
Czytaj oryginał (ang.) |
| Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales |
On Wednesday, British multinational pharmaceutical GSK Plc GSK reported first-quarter sales of $9.46 billion (7.52 billion Sterling Pounds), up 2% year-over-year and 4% on constant currency. Analysts had estimated sales of $7.46 billion. |
benzinga.com |
2025-04-30 13:27:55 |
Czytaj oryginał (ang.) |
| GSK Jumps On Solid Earnings, Says It's 'Well Positioned' To Navigate Tariffs |
GSK stock jumped early Wednesday after the drugmaker reported adjusted earnings of $1.20 per share on $10.06 billion in first-quarter sales. |
investors.com |
2025-04-30 13:12:16 |
Czytaj oryginał (ang.) |
| GSK Posts Strong Results, Says 'Well Positioned' in Case of Pharma Tariffs |
U.S.-listed shares of GSK (GSK) are gaining in premarket trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the Trump administration imposes tariffs against the industry. |
investopedia.com |
2025-04-30 13:06:23 |
Czytaj oryginał (ang.) |
| GSK's Nucala approved in China for treating nasal polyps |
GSK PLC's (LSE:GSK, NYSE:GSK) Nucala (mepolizumab) has been approved in China to treat adults with chronic rhinosinusitis with nasal polyps (CRSwNP) when other therapies, like steroids or surgery, have not worked. This makes Nucala the first anti-interleukin-5 treatment available for this condition in China, where an estimated 30 million people live with CRSwNP. |
proactiveinvestors.co.uk |
2025-01-03 04:30:10 |
Czytaj oryginał (ang.) |
| GSK's FIRST trial achieves progression-free survival milestone in advanced ovarian cancer |
GSK PLC (LSE:GSK, NYSE:GSK) has announced that its phase III FIRST-ENGOT-OV44 trial met its primary goal, or 'endpoint'. The study showed that the addition of Jemperli (dostarlimab) to platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab, significantly improved progression-free survival (PFS) in first-line advanced ovarian cancer. |
proactiveinvestors.co.uk |
2024-12-20 05:46:26 |
Czytaj oryginał (ang.) |
| GSK's cancer drugs meet progression-free survival goal in late-stage trial |
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial. |
reuters.com |
2024-12-20 04:35:25 |
Czytaj oryginał (ang.) |
| GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli |
The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older. |
zacks.com |
2024-12-17 13:46:15 |
Czytaj oryginał (ang.) |
| GSK passes three significant milestones with new cancer drug given a double boost |
GSK PLC (LSE:GSK, NYSE:GSK) has announced significant progress in its oncology pipeline, achieving three milestones. The European Medicines Agency (EMA) has issued a positive opinion recommending the expanded approval of Jemperli (dostarlimab) with chemotherapy for first-line treatment of advanced or recurrent endometrial cancer. |
proactiveinvestors.co.uk |
2024-12-16 05:21:51 |
Czytaj oryginał (ang.) |
| GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold? |
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve. |
zacks.com |
2024-12-11 13:21:09 |
Czytaj oryginał (ang.) |
| Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis |
FOR IMMEDIATE RELEASE Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis |
globenewswire.com |
2024-12-10 09:00:00 |
Czytaj oryginał (ang.) |
| Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis |
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry leader in deploying computation and experimentation to drug discovery, today announced two multi-program strategic collaborations with GSK. The collaborations will focus on the identification and validation of novel therapeutic targets for fibrotic diseases and osteoarthritis. |
globenewswire.com |
2024-12-10 04:00:00 |
Czytaj oryginał (ang.) |
| GSK says blood cancer drug shows dramatic survival gains in key trial |
GSK PLC (LSE:GSK, NYSE:GSK) shares in New York rose Monday afternoon after it announced that its blood cancer drug Blenrep (belantamab mafodotin) significantly extended survival in a pivotal trial. The drug, combined with two other therapies, reduced the risk of death by 42% compared to a rival treatment from Johnson & Johnson (NYSE:JNJ), according to results presented at the American Society of Hematology's annual meeting. |
proactiveinvestors.com |
2024-12-09 16:46:13 |
Czytaj oryginał (ang.) |
| GSK's drug combo shown to cut risk of death by 42% in type of blood cancer |
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment. |
reuters.com |
2024-12-09 15:37:14 |
Czytaj oryginał (ang.) |
| FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD |
The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review. |
zacks.com |
2024-12-09 14:30:19 |
Czytaj oryginał (ang.) |
| Final Trades: Oracle, Vertiv Holdings and GSK |
The Investment Committee give you their top stocks to watch for the second half. |
youtube.com |
2024-12-06 15:28:36 |
Czytaj oryginał (ang.) |
| GSK Expands Vaccine Collaboration With Zhifei in China |
GSK expands the licensing deal with Zhifei to market its shingles vaccine in China for an additional eight years till 2034. |
zacks.com |
2024-12-05 14:55:24 |
Czytaj oryginał (ang.) |
| GSK extends vaccine partnership with Zhifei in China |
GSK PLC (LSE:GSK, NYSE:GSK) has extended its partnership with Chongqing Zhifei Biological Products (Zhifei) to bring its shingles vaccine, Shingrix, to mainland China through 2034. The revised agreement builds on a previous three-year deal and includes exclusive rights for Zhifei to import, distribute, and promote Shingrix. |
proactiveinvestors.co.uk |
2024-12-05 05:51:53 |
Czytaj oryginał (ang.) |
| GSK, China's Zhifei Expand Shingles Shot Collaboration |
GSK extended its collaboration with Zhifei to commercialize its shingles vaccine Shingrix in China until 2034. |
wsj.com |
2024-12-05 05:40:00 |
Czytaj oryginał (ang.) |
| GSK expands deal with China's Zhifei to explore RSV vaccine collaboration |
GSK said on Thursday it has expanded its agreement with China's Zhifei to explore a collaboration with the Chinese vaccines company on the British drugmaker's respiratory syncytial virus (RSV) vaccine, Arexvy. |
reuters.com |
2024-12-05 04:29:03 |
Czytaj oryginał (ang.) |
| GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo |
The European Commission approves fully liquid presentation of GSK's meningococcal vaccine, Menveo, to protect against invasive meningococcal disease. |
zacks.com |
2024-11-28 13:26:12 |
Czytaj oryginał (ang.) |
| Anson Resources unique chemical-free lithium brine pre-treatment used in successful DLE testing |
Anson Resources Ltd (ASX:ASN, OTCQB:ANSNF) has successfully tested its chemical-free lithium brine pre-treatment process that reduces iron in brine, with the iron-free brine successfully used as feed for the KOCH Direct Lithium Extraction (DLE) pilot at Green River in Utah, USA. Anson’s unique lithium brine pre-treatment process reduces iron content to less than 1 ppm without the use of chemicals and was developed at the Anson Lithium Innovation Center (LIC) in the USA. Since achieving an iron content of less than 1 part per million in the feed brine, approximately 122,000 litres of lithium eluate has been produced by using the Koch DLE process. Traditional methods used in brine pre-treatment require chemicals to precipitate iron from the feedstock, which is more expensive, less environmentally friendly and time-consuming. Anson is focused on reducing costs in its lithium extraction flowsheet design to maximise shareholder value, while also reducing the environmental impact of the lithium extraction process. “This innovation is an important step in the development of a flow chart for the extraction of lithium from deep well brine,” Anson executive chair and CEO Bruce Richardson said. “Anson’s objective is to produce a product for the use in electric vehicles, the key intention of EVs is to lower carbon emissions, which is a primary focus of potential offtake partners with which the company is engaged in discussions. “We also note that European governments are increasingly focused on lowering the carbon intensity of the EV value chain. “Given these factors, we continue to develop innovative processes that will deliver the highest economic returns for our shareholders while lowering the impact on the environment. “Our iron removal process achieves both of these objectives by lowering costs and eliminating the use of chemicals. “We are continuing our work with Koch in maximizing the recovery of lithium from the Green River Lithium Project brine and look forward to the results in early 2025.” The lithium eluate produced using the KOCH DLE technology will be processed through Anson downstream Sample Demonstration Plant (SDP) to produce lithium carbonate. Anson says that the KOCH DLE test-work is expected to continue until February 2025 and will produce additional lithium eluate for further downstream processing test-work. Two full tanks containing 32,000 gallons of lithium eluate processed by the Koch DLE at Green River, Utah, USA. GSK PLC (LSE:GSK, NYSE:GSK) has received approval from the European Commission for a new, fully liquid version of its Menveo vaccine, which protects against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W, and Y. This updated formulation eliminates the need for reconstitution before use, simplifying the vaccination process for healthcare providers. The vaccine is now licensed for use in children from age two, as well as adolescents and adults. GSK highlighted the importance of this development in improving vaccine accessibility and uptake, especially among at-risk groups like young children and teenagers. IMD is a serious, unpredictable illness that can lead to life-threatening complications. Even with treatment, up to one in six patients may die, and survivors may face long-term effects such as hearing loss, neurological damage, or amputations. The approval follows positive results from two Phase IIb trials, which showed the new liquid formulation offers similar effectiveness, safety, and tolerability as the earlier version. GSK’s head of vaccines research, Philip Dormitzer, emphasised the company’s commitment to preventing bacterial meningitis and supporting public health efforts across the EU. |
https://www.proactiveinvestors.com |
2024-11-27 08:45:00 |
Czytaj oryginał (ang.) |
| GSK's receives European Commission green light for liquid form of key vaccine |
GSK PLC (LSE:GSK, NYSE:GSK) has received approval from the European Commission for a new, fully liquid version of its Menveo vaccine, which protects against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W, and Y. This updated formulation eliminates the need for reconstitution before use, simplifying the vaccination process for healthcare providers. |
proactiveinvestors.co.uk |
2024-11-27 05:07:55 |
Czytaj oryginał (ang.) |
| FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma |
The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025. |
zacks.com |
2024-11-26 13:25:21 |
Czytaj oryginał (ang.) |